Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 2
1993 2
1994 4
1995 7
1996 8
1997 12
1998 25
1999 16
2000 25
2001 22
2002 15
2003 27
2004 20
2005 26
2006 18
2007 35
2008 26
2009 32
2010 18
2011 27
2012 25
2013 29
2014 27
2015 30
2016 36
2017 21
2018 28
2019 25
2020 27
2021 34
2022 28
2023 25
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

663 results

Results by year

Filters applied: . Clear all
Page 1
KAI1/CD82 gene and autotaxin-lysophosphatidic acid axis in gastrointestinal cancers.
Wang S, Chen J, Guo XZ. Wang S, et al. World J Gastrointest Oncol. 2022 Aug 15;14(8):1388-1405. doi: 10.4251/wjgo.v14.i8.1388. World J Gastrointest Oncol. 2022. PMID: 36160748 Free PMC article. Review.
The KAI1/CD82 gene inhibits the metastasis of most tumors and is remarkably correlated with tumor invasion and prognosis. ...Clarifying the mechanism of ATX-LPA in the inhibition of cancer metastasis by KAI1/CD82 will provide an important theoretical basis for targe …
The KAI1/CD82 gene inhibits the metastasis of most tumors and is remarkably correlated with tumor invasion and prognosis. ...Clarifyi …
Targeting CD82/KAI1 for Precision Therapeutics in Surmounting Metastatic Potential in Breast Cancer.
Viera M, Yip GWC, Shen HM, Baeg GH, Bay BH. Viera M, et al. Cancers (Basel). 2021 Sep 6;13(17):4486. doi: 10.3390/cancers13174486. Cancers (Basel). 2021. PMID: 34503296 Free PMC article. Review.
Such an approach would entail the selection of a subset of breast cancer patients with low levels of CD82, and instituting an appropriate treatment scheme tailored towards restoring the levels of CD82 in this group of patients. Proposed precision treatment regimens …
Such an approach would entail the selection of a subset of breast cancer patients with low levels of CD82, and instituting an appropr …
Role of Metastasis Suppressor KAI1/CD82 in Different Cancers.
Yan W, Huang J, Zhang Q, Zhang J. Yan W, et al. J Oncol. 2021 Jul 9;2021:9924473. doi: 10.1155/2021/9924473. eCollection 2021. J Oncol. 2021. PMID: 34306081 Free PMC article. Review.
Considering its pathological and physiological significance, KAI1/CD82 could be a potential strategy for clinical predicting and preventing tumor progression and metastasis. The present review aims to discuss the role of KAI1/CD82 in metastasis for different cancers …
Considering its pathological and physiological significance, KAI1/CD82 could be a potential strategy for clinical predicting and prev …
CD82-TRPM7-Numb signaling mediates age-related cognitive impairment.
Zhao Y, Kiss T, DelFavero J, Li L, Li X, Zheng L, Wang J, Jiang C, Shi J, Ungvari Z, Csiszar A, Zhang XA. Zhao Y, et al. Geroscience. 2020 Apr;42(2):595-611. doi: 10.1007/s11357-020-00166-4. Epub 2020 Feb 22. Geroscience. 2020. PMID: 32088828 Free PMC article.
CD82 overexpression promoted beta-amyloid peptide (Abeta) secretion which could be reversed by Numb T346S348 mutants. Importantly, hippocampus-related memory functions were improved in Cd82(-/-) mice. Taken together, our findings provide the evidence that links the …
CD82 overexpression promoted beta-amyloid peptide (Abeta) secretion which could be reversed by Numb T346S348 mutants. Importantly, hi …
CD82 controls CpG-dependent TLR9 signaling.
Khan NS, Lukason DP, Feliu M, Ward RA, Lord AK, Reedy JL, Ramirez-Ortiz ZG, Tam JM, Kasperkovitz PV, Negoro PE, Vyas TD, Xu S, Brinkmann MM, Acharaya M, Artavanis-Tsakonas K, Frickel EM, Becker CE, Dagher Z, Kim YM, Latz E, Ploegh HL, Mansour MK, Miranti CK, Levitz SM, Vyas JM. Khan NS, et al. FASEB J. 2019 Nov;33(11):12500-12514. doi: 10.1096/fj.201901547R. Epub 2019 Aug 13. FASEB J. 2019. PMID: 31408613 Free PMC article.
However, the mechanisms by which CD82 participates in innate immunity are unknown. We report that CD82 is a key regulator of TLR9 trafficking and signaling. ...Moreover, CD82 is essential for TLR9-dependent myddosome formation in response to CpG stimulation. …
However, the mechanisms by which CD82 participates in innate immunity are unknown. We report that CD82 is a key regulator of T …
KAI1/CD82, Metastasis Suppressor Gene as a Therapeutic Target for Non-Small-Cell Lung Carcinoma.
Prabhu VV, Devaraj SN. Prabhu VV, et al. J Environ Pathol Toxicol Oncol. 2017;36(3):269-275. doi: 10.1615/JEnvironPatholToxicolOncol.2017024619. J Environ Pathol Toxicol Oncol. 2017. PMID: 29283339 Review.
KAI1/CD82 suppresses metastasis via multiple mechanisms regulating inhibition of cell motility, adhesion, fusion, and proliferation. ...The differential expression of KAI1/CD82 could prove to be of novel therapeutic significance in treating malignant tumors and in r …
KAI1/CD82 suppresses metastasis via multiple mechanisms regulating inhibition of cell motility, adhesion, fusion, and proliferation. …
Inhibition of CD82 improves colitis by increasing NLRP3 deubiquitination by BRCC3.
Kim JS, Kim HK, Lee J, Jang S, Cho E, Mun SJ, Yoon S, Yang CS. Kim JS, et al. Cell Mol Immunol. 2023 Feb;20(2):189-200. doi: 10.1038/s41423-022-00971-1. Epub 2023 Jan 5. Cell Mol Immunol. 2023. PMID: 36600050 Free PMC article.
Herein, we show that although CD82 suppressed the activation of the NLRP3 inflammasome in vivo and in vitro, CD82 deficiency decreased the severity of colitis in mice. Furthermore, two binding partners of CD82, NLRP3 and BRCC3, were identified. CD82 bi …
Herein, we show that although CD82 suppressed the activation of the NLRP3 inflammasome in vivo and in vitro, CD82 deficiency d …
CD82 metastasis suppressor gene: a potential target for new therapeutics?
Tonoli H, Barrett JC. Tonoli H, et al. Trends Mol Med. 2005 Dec;11(12):563-70. doi: 10.1016/j.molmed.2005.10.002. Epub 2005 Nov 3. Trends Mol Med. 2005. PMID: 16271511 Review.
Recent studies suggest that complex mechanisms underlie CD82 loss of function, including altered transcriptional regulation, splice variant production and post-translational protein modifications, and indicate a central role for CD82 in controlling metastasis as a ' …
Recent studies suggest that complex mechanisms underlie CD82 loss of function, including altered transcriptional regulation, splice v …
CD82 and Gangliosides Tune CD81 Membrane Behavior.
Fernandez L, Malrieu M, Bénistant C, Dosset P, Rubinstein E, Odintsova E, Berditchevski F, Milhiet PE. Fernandez L, et al. Int J Mol Sci. 2021 Aug 6;22(16):8459. doi: 10.3390/ijms22168459. Int J Mol Sci. 2021. PMID: 34445169 Free PMC article.
More specifically, we found that CD82 expression increases the dynamics of CD81 and alters its localization at the plasma membrane, this has no effect on the behavior of CD9. ...We predict that CD82 may act as a regulator of the lateral segregation of specific tetra …
More specifically, we found that CD82 expression increases the dynamics of CD81 and alters its localization at the plasma membrane, t …
663 results